Department of Clinical Laboratory, Tangshan Gongren Hospital, No. 27, Wenhua Road, Lubei District, Tangshan City, Hebei Province, China.
Department of Respiration, Tangshan Gongren Hospital, No. 27, Wenhua Road, Lubei District, Tangshan City, Hebei Province, China.
Biomed Res Int. 2022 Oct 17;2022:1394042. doi: 10.1155/2022/1394042. eCollection 2022.
Lung cancer mortality and morbidity rates are the first among malignant tumors. It is extremely crucial to pay more attention to the early diagnosis and treatment of lung cancer and to grasp and judge the progress of the patient's condition promptly. In this study, lung cancer patients' early diagnosis with tumor markers and inflammatory variables is examined. The general surgery department of our hospital treated 98 patients with lung cancer and 100 patients with benign pulmonary hyperplasia from January 2017 to February 2018. Additionally, 100 healthy subjects who completed physical examinations during this time period were included. Based on the findings of the pathological examination, 100 patients with benign pulmonary hyperplasia were chosen as the benign group, 100 patients with lung cancer were chosen as the malignant group, and 100 healthy individuals were chosen as the healthy group. The tumor markers carbohydrate antigen 125 (CA125), CA153, and carcinoembryonic antigen (CEA), as well as inflammatory factors such as tumor necrosis factor- (TNF-) and high-sensitivity C-reactive protein, were measured in the venous blood of three groups of patients (hs-CRP). There was no discernible difference in tumor marker levels between the benign and healthy groups ( > 0.05). In comparison to the benign and healthy groups, the malignant group had higher serum levels of CA153, CA125, and CEA ( 0.05). Between the benign and healthy groups, there was no discernible difference in the levels of inflammatory factors ( > 0.05). TNF- and hs-CRP serum levels were observed to be higher in the malignant group compared to the benign and healthy groups ( 0.05). The combined detection of CA153 + CA125 + CEA + TNF - +hs - CRP showed the highest sensitivity and specificity, which were, respectively, 62.22 percent and 92.00 percent, when compared to single or mixed detection of tumor markers or inflammatory factors solely. Serum levels of inflammatory agents TNF- and hs-CRP may be related to the pathophysiology and other functions of patients with lung cancer, as well as to the development and metastasis of the disease. These markers include CA153, CA125, and CEA. For the early detection of lung cancer and the evaluation of the disease's severity, the detection of tumor markers in combination with inflammatory variables has a significant reference value.
肺癌的死亡率和发病率均居恶性肿瘤之首。因此，对于肺癌患者，更加注重早期诊断和治疗，及时掌握和判断患者病情的进展至关重要。本研究旨在探讨肿瘤标志物和炎症变量对肺癌患者的早期诊断价值。选取我院普外科 2017 年 1 月至 2018 年 2 月收治的肺癌患者 98 例、良性肺增生患者 100 例，同时选取同期健康体检者 100 例，均纳入研究。其中良性肺增生患者经病理检查确诊为良性组 100 例，肺癌患者经病理检查确诊为恶性组 100 例，同期健康体检者为健康组 100 例。采用酶联免疫吸附法检测三组患者静脉血中的肿瘤标志物糖类抗原 125（CA125）、CA153、癌胚抗原（CEA）及炎症因子肿瘤坏死因子-（TNF-）、高敏 C 反应蛋白（hs-CRP）。良性组与健康组肿瘤标志物水平比较差异无统计学意义（>0.05），恶性组血清 CA153、CA125、CEA 水平明显高于良性组和健康组（均<0.05）。良性组与健康组炎症因子水平比较差异无统计学意义（>0.05），恶性组 TNF-、hs-CRP 水平明显高于良性组和健康组（均<0.05）。CA153+CA125+CEA+TNF-+hs-CRP 联合检测灵敏度、特异度分别为 62.22%、92.00%，均高于单一或混合检测肿瘤标志物或炎症因子（均<0.05）。血清炎症因子 TNF-、hs-CRP 可能与肺癌患者的病理生理改变及其它功能改变、疾病的发生发展及转移等有关，与 CA153、CA125、CEA 等标志物联合检测对肺癌的早期诊断及判断病情严重程度具有重要的参考价值。
